Aptinyx Annual Revenue, Number of Employees, Growth and Funding


Chicago, IL USA
Total Funding:$237.4M
Lead Investor(s):Bain Capital Life Sciences

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Aptinyx's estimated annual revenue is currently $6.7M per year.
  • Aptinyx received $70.0M in venture funding in December 2017.
  • Aptinyx's estimated revenue per employee is $112,000
  • Aptinyx's total funding is $237.4M.

Employee Data

  • Aptinyx has 60 Employees.
  • Aptinyx grew their employee count by -14% last year.
  • Aptinyx currently has 1 job openings.

Executive Contacts

Sarah TorriSenior Director, Clinical Development
Tony SmolcichSenior Director Information Technology at Aptinyx
Katie HardekDirector, Human Resources
Amber JohnsonAssociate Director of Finance
Nick SmithDirector, Corporate Development
Torsten MeldgaardChief Medical Officer at Aptinyx
David HouckChief Development Officer
Andy KiddChief Operating Officer
Norbert RiedelPresident/CEO
Ashish KhannaChief Financial Officer and Chief Business Officer

Welcome to our company page and thank you for your interest in Aptinyx Inc. Aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more, please visit our website at www.aptinyx.com.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Heidolph North ...
Project Farma
Project Farma

Aptinyx News

09/03/2019 - Aptinyx Reports Second Quarter 2019 Financial Results and ...

EVANSTON, Ill., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing ...

09/08/2019 - Aptinyx Inc.'s (APTX) CEO Norbert Riedel on Q2 2019 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX) Q2 2019 Results Earnings Conference Call August 12, 2019 8:00 AM ET. Company Participants. Nick Smith ...

09/03/2019 - Form 8-K Aptinyx Inc. For: Aug 12

On August 12, 2019, Aptinyx Inc., issued a press release announcing its financial results for the quarter ended June 30, 2019. A copy of the ...

Aptinyx Funding

DateAmountRoundLead InvestorsReference
2016-05-10$65.0MANew Leaf Venture PartnersArticle
2017-12-19$70.0MBBain Capital Life SciencesArticle

Aptinyx Executive Hires

2017-12-08Andy KiddChief commercial officerArticle
2018-02-14Ashish KhannaChief Financial Officer and Chief Business OfficerArticle
2018-05-04David HouckChief Development OfficerArticle